公开(公告)号：US11181803B2

公开(公告)日：2021-11-23

申请号：US16248589

申请日：2019-01-15

Applicant: ProLynx LLC

Inventor： Gary W. Ashley ,  Daniel V. Santi ,  Jeffrey C. Henise

IPC: A61K47/61 ,  G02F1/361 ,  A61K47/69 ,  A61K47/60 ,  A61L15/44 ,  A61L15/60 ,  A61L15/64 ,  A61L27/54 ,  A61L27/58 ,  C07C317/18 ,  C08J3/075 ,  C09B23/01 ,  A61K47/34 ,  A61L15/26 ,  A61L27/18 ,  A61L27/52 ,  C07C271/08

Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

公开(公告)号：US20200270225A1

公开(公告)日：2020-08-27

申请号：US16850425

申请日：2020-04-16

Applicant: Intrexon Corporation

Inventor： Robert Eugene Hormann ,  Bing Li

IPC: C07D333/38 ,  C07C243/38 ,  C07C281/02 ,  C12N15/82 ,  A01N37/18 ,  A01N43/08 ,  A01N43/10 ,  A01N43/30 ,  A01N43/32 ,  A01N43/40 ,  C07C241/04 ,  C07C269/06 ,  C07C271/08 ,  C07D213/82 ,  C07D307/68 ,  C07D317/68 ,  C07D319/18 ,  C07D217/24

Abstract: The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

公开(公告)号：US20190209691A1

公开(公告)日：2019-07-11

申请号：US16248537

申请日：2019-01-15

Applicant: ProLynx LLC

Inventor： Gary W. ASHLEY ,  Daniel V. SANTI ,  Jeffrey C. HENISE

IPC: A61K47/34 ,  A61L27/52 ,  C07C317/18 ,  A61L15/26 ,  C07C271/08 ,  A61L27/18 ,  C08J3/075 ,  A61K47/60 ,  A61K47/61 ,  A61L15/64 ,  A61L15/60 ,  A61L15/44 ,  A61L27/58 ,  A61L27/54 ,  A61K47/69

CPC classification number: A61K47/34 ,  A61K47/60 ,  A61K47/61 ,  A61K47/6903 ,  A61L15/26 ,  A61L15/44 ,  A61L15/60 ,  A61L15/64 ,  A61L27/18 ,  A61L27/52 ,  A61L27/54 ,  A61L27/58 ,  C07C271/08 ,  C07C317/18 ,  C08G2650/30 ,  C08J3/075 ,  C08J2300/16 ,  C08J2305/08 ,  C08J2371/02

Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

公开(公告)号：US20170349541A1

公开(公告)日：2017-12-07

申请号：US15632847

申请日：2017-06-26

Applicant: SK Biopharmaceuticals Co., Ltd.

Inventor： Sung James Lee ,  Susan Marie Melnick

IPC: C07C271/08 ,  A61K31/137 ,  A61K31/223 ,  A61K31/27

CPC classification number: C07C271/08 ,  A61K31/137 ,  A61K31/223 ,  A61K31/27

Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

公开(公告)号：US09688620B2

公开(公告)日：2017-06-27

申请号：US14495416

申请日：2014-09-24

Applicant: SK Biopharmaceuticals Co., Ltd.

Inventor： Sung James Lee ,  Susan Marie Melnick

IPC: C07C271/08 ,  A61K31/137 ,  A61K31/223 ,  A61K31/27

CPC classification number: C07C271/08 ,  A61K31/137 ,  A61K31/223 ,  A61K31/27

Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

公开(公告)号：US20150197502A1

公开(公告)日：2015-07-16

申请号：US14667622

申请日：2015-03-24

Applicant: Cardioxyl Pharmaceuticals, Inc. ,  The Johns Hopkins University

Inventor： John P. Toscano ,  Art Sutton ,  Vincent J. Kalish ,  Frederick Arthur Brookfield ,  Stephen Martin Courtney ,  Lisa Marie Frost

IPC: C07D333/34 ,  C07C233/01 ,  C07C271/08 ,  C07D213/71 ,  C07C317/28 ,  C07D295/215 ,  C07D307/82 ,  C07D207/16 ,  C07C233/64 ,  C07C317/32

CPC classification number: C07D333/34 ,  C07C233/01 ,  C07C233/64 ,  C07C259/06 ,  C07C259/10 ,  C07C271/08 ,  C07C311/51 ,  C07C311/53 ,  C07C317/14 ,  C07C317/28 ,  C07C317/32 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/16 ,  C07D213/40 ,  C07D213/71 ,  C07D295/205 ,  C07D295/215 ,  C07D307/82 ,  C07D309/12

Abstract: The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

Abstract translation: 本发明提供某些双酰化羟胺衍生物化合物，包含这些化合物的药物组合物和试剂盒，以及使用这些化合物或药物组合物的方法。 特别地，本发明提供了使用这些化合物或药物组合物治疗，预防或延缓疾病或病症发作和/或发展的方法。 在一些实施方案中，疾病或病症选自心血管疾病，缺血，再灌注损伤，癌性疾病，肺动脉高压和对硝酰基治疗有反应的病症。

公开(公告)号：US08598297B2

公开(公告)日：2013-12-03

申请号：US11665119

申请日：2005-10-24

Applicant: Erdem Bedri ,  Debkumar Bhattacharjee ,  John N. Argyropoulos

Inventor： Erdem Bedri ,  Debkumar Bhattacharjee ,  John N. Argyropoulos

IPC: C08G18/42 ,  C08G18/10 ,  C09J175/06 ,  C08L75/06 ,  C07C271/08

CPC classification number: C08G18/36 ,  C08G18/0866 ,  C08G18/4288

Abstract: Prepolymers are prepared by a reaction of a polyisocyanate and a hydroxylmethyl containing polyester polyol derived from a fatty acid. The prepolymers can be prepared having isocyanate, hydroxyl, or a variety of other reactive functional groups. The prepolymers are useful in making polyurethanes and other polymers, or a crosslinking agents.

Abstract translation: 预聚物通过多异氰酸酯和衍生自脂肪酸的含羟甲基的聚酯多元醇的反应制备。 预聚物可以制备成具有异氰酸酯，羟基或各种其它反应性官能团。 预聚物可用于制备聚氨酯和其它聚合物，或交联剂。

公开(公告)号：US20120178805A1

公开(公告)日：2012-07-12

申请号：US13418877

申请日：2012-03-13

Applicant: Yousef Al-Abed

Inventor： Yousef Al-Abed

IPC: A61K31/27 ,  C07C311/49 ,  C07C271/08 ,  A61P37/06 ,  A61K31/166 ,  A61K31/18 ,  A61P29/00 ,  C07C251/86 ,  A61K31/15

CPC classification number: C07C251/86 ,  C07C281/02 ,  C07C311/49

Abstract: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.

Abstract translation: 提供式（I）的各种化合物：还提供包含上述化合物的药物组合物。 此外，提供了哺乳动物抑制巨噬细胞迁移抑制因子（MIF）活性的方法，以及治疗或预防哺乳动物炎症的方法。 还提供了治疗具有败血症，败血病和/或内毒素性休克的哺乳动物的方法。 还提供了治疗具有自身免疫疾病的哺乳动物的方法以及治疗具有肿瘤的哺乳动物的方法。

公开(公告)号：US20120157386A1

公开(公告)日：2012-06-21

申请号：US13325453

申请日：2011-12-14

Applicant: Cameron SMITH ,  Melissa FLEURY ,  Roland GENDRON ,  Ryan HUDSON ,  Adam D. HUGHES

Inventor： Cameron SMITH ,  Melissa FLEURY ,  Roland GENDRON ,  Ryan HUDSON ,  Adam D. HUGHES

IPC: A61K31/415 ,  C07C229/34 ,  C07D231/14 ,  C07D401/06 ,  A61K31/4439 ,  C07D413/06 ,  A61K31/5377 ,  A61K31/42 ,  A61P7/02 ,  A61P3/10 ,  A61P1/12 ,  A61P27/06 ,  A61P3/06 ,  A61P25/00 ,  A61K31/704 ,  A61P7/10 ,  A61P21/02 ,  A61P29/00 ,  A61K38/02 ,  A61P9/12 ,  A61P9/04 ,  A61P13/12 ,  C07C271/08

CPC classification number: C07D471/04 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  C07C281/02 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D231/40 ,  C07D237/14 ,  C07D237/24 ,  C07D239/28 ,  C07D239/34 ,  C07D239/36 ,  C07D239/52 ,  C07D239/54 ,  C07D249/04 ,  C07D249/10 ,  C07D249/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/12 ,  C07D261/18 ,  C07D263/32 ,  C07D263/34 ,  C07D263/38 ,  C07D277/34 ,  C07D277/56 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D413/04 ,  Y02P20/55

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract translation: 一方面，本发明涉及具有下式的化合物：其中R 1 -R 6，a，b和X如说明书中所定义，或其药学上可接受的盐。 这些化合物具有去血清抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。

公开(公告)号：US20110028701A1

公开(公告)日：2011-02-03

申请号：US12891596

申请日：2010-09-27

Applicant: Kazutake HAGIYA ,  Takashi SUGIMURA

Inventor： Kazutake HAGIYA ,  Takashi SUGIMURA

IPC: C09B27/00 ,  C07C271/08

CPC classification number: C07C281/20

Abstract: Provided is an industrially safe and useful azodicarboxylic acid bis(2-alkoxyethyl) ester compound that is useful for the Mitsunobu reaction in which it is used in combination with a phosphorus compound to carry out a dehydration condensation reaction, and also useful as an oxidizing agent, and a starting material for various synthetic processes. Also provided are a production intermediate of the above-described compound, and methods for producing these compounds. An azodicarboxylic acid bis(2-alkoxyethyl) ester compound represented by formula (1); wherein A represents an alkyl group having 1 to 10 carbon atoms.

Abstract translation: 本发明提供工业上安全有用的偶氮二羧酸双（2-烷氧基乙基）酯化合物，其可用于Mitsunobu反应，其与磷化合物组合用于进行脱水缩合反应，并且还可用作氧化剂 ，以及各种合成方法的原料。 还提供了上述化合物的制备中间体以及这些化合物的制备方法。 由式（1）表示的偶氮二羧酸双（2-烷氧基乙基）酯化合物; 其中A表示碳原子数1〜10的烷基。